897656-36-9

Basic information

• Product Name: Benzamide, N-methoxy-N-methyl-4-(trifluoromethoxy)-
• Synonyms: 4-hydroxy-N-methoxy-N-methyl-benzamide;N-methoxy-N-methyl-4-trifluoromethoxybenzamide
• CAS NO: 897656-36-9
• Molecular Formula: C10H10F3NO3
• Molecular Weight: 249.19
• Mol File: 897656-36-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzamide, N-methoxy-N-methyl-4-(trifluoromethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-methoxy-N-methyl-4-(trifluoromethoxy)-(897656-36-9)
• EPA Substance Registry System: Benzamide, N-methoxy-N-methyl-4-(trifluoromethoxy)-(897656-36-9)

Safety Data

• Hazardous Substances Data: 897656-36-9(Hazardous Substances Data)

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 330-12-1 4-trifluoromethoxybenzoic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 36823-88-8 4-(trifluoromethoxy)benzoyl chloride 

Downstream Products

• 897656-40-5 (4-trifluoromethoxyphenyl)-(3-methoxythiophen-2-yl)-methanone 
• 1111139-39-9 C₁₂H₁₄F₃NO₂ 
• 130339-50-3 1-[4-(trifluoromethoxy)phenyl]propan-1-amine 
• 94108-55-1 1-(4-(trifluoromethoxy)phenyl)propan-1-one 
• 98566-93-9 bis(4-(trifluoromethoxy)phenyl)methanone 

Relevant articles and documents

MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF

The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

SMALL MOLECULE LFA-1 INHIBITORS

The present invention relates to novel compounds which are capable of inhibiting the interaction of LFA-1 with its counter ligands.

Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors

A series of 3-aryl-3-azolylpropan-1-amines was prepared and screened for its capability of inhibiting monoamine reuptake. Analogs with nanomolar potency, good human in vitro microsomal stability, and low drug-drug interaction potential were described. In